[RESEARCH BLOG] · 2026-07-30
Alumis Inc. (ALMS) – Sell Signal Amid Recovery‑Mode Market Pulse and Weak Fundamentals
By Pierre Brunelle · Founder & Research Lead
Alumis Inc. closed at $26.38, down 2.40 % on the Wednesday session of 2026‑07‑29 (as of 2026‑07‑29). The LOPJLB proprietary scanner now flags the stock with a SELL directional signal and a ‑5 score while the broader market regime is classified as RECOVERY.
Alumis has been the subject of several recent headlines that together paint a mixed picture of short‑term price momentum and longer‑term operational risk.
-
The defense‑focused outlet DefenseWorld.net reported on 2026‑07‑19 that Alumis shares had risen 5.7 % in the prior session, prompting speculation about what could be driving the bounce. The article noted that the uptick followed a modest improvement in the company’s cash‑burn profile disclosed in its latest quarterly filing, but it stopped short of attributing the move to any new clinical data.
-
On 2026‑06‑25, Seeking Alpha published a deep‑dive titled “Alumis: Is Envudeucitinib The ‘Real Deal?’ We Should Find Out Soon.” The piece highlighted that Alumis’s TYK2 inhibitor, envudeucitinib, is slated for a pivotal Phase III readout later in the year, yet the author cautioned that the drug’s efficacy signal remains unproven and that the market may be pricing in optimistic assumptions about regulatory approval.
Source: Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
-
Earlier in the quarter, The Motley Fool ran a series of stories documenting a dramatic price surge.
- On 2026‑05‑24, the outlet noted a 355 % rally after a hedge fund disclosed a $169 million stake in Alumis.
Source: This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
- A follow‑up on 2026‑05‑17 described a 400 % increase tied to an additional $8 million purchase by Cormorant Capital.
Source: Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
- By 2026‑05‑15, the same publication reported that a major healthcare investor had begun cutting back its position, hinting at possible concerns over the sustainability of the rally.
Source: Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
- On 2026‑05‑24, the outlet noted a 355 % rally after a hedge fund disclosed a $169 million stake in Alumis.
-
Finally, GlobeNewswire released Alumis’s Q1 2026 financial results on 2026‑05‑14, emphasizing milestones such as the initiation of a Phase I trial for the CNS‑penetrant TYK2 inhibitor A‑005. The press release underscored the company’s continued investment in R&D but also disclosed a net loss that widened year‑over‑year, reinforcing the cash‑flow challenges that have haunted the firm since its inception.
Source: Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
Fundamentals and Valuation
Alumis’s balance sheet and income statement continue to reflect a company in the deep‑loss phase typical of many clinical‑stage biotech firms, but the magnitude of the deficits is unusually severe. The trailing twelve‑month (TTM) price‑to‑earnings ratio sits at ‑14.15, indicating that earnings are negative and that the market is effectively pricing the stock at a discount to a zero‑earnings baseline. The enterprise‑value‑to‑EBITDA multiple mirrors this distress, standing at ‑7.99.
Revenue growth is in free‑fall, with a ‑90 % year‑over‑year change reported in the fundamentals snapshot. Gross margins remain high at 89.63 %, a reflection of the low cost of goods sold for a company that has yet to commercialize a product. However, operating margins are ‑5,364 % and net margins ‑2,825.7 %, underscoring that operating expenses and R&D outlays dwarf the modest revenue stream.
Return on invested capital (ROIC) is ‑32.78 %, while return on equity (ROE) and return on assets (ROA) are ‑64.57 % and ‑35.35 %, respectively, confirming that the firm is eroding shareholder value on a per‑share and per‑asset basis. Free‑cash‑flow yield is ‑11.30 %, indicating that the company is consuming cash rather than generating it.
The company’s leverage is notable: debt‑to‑equity (D/E) stands at 6.29, and interest coverage is effectively nonexistent, with an “interest coverage” metric listed as 999.0 (a placeholder indicating insufficient earnings to cover interest). The Altman Z‑score, a bankruptcy risk indicator, is 15.69, a surprisingly high figure that suggests the model’s inputs are distorted by the negative earnings rather than indicating genuine financial health.
Analyst consensus targets the stock at $39.17, with a Buy recommendation. This optimism is at odds with the deteriorating fundamentals and drives the current SELL signal from LOPJLB.
Below is a concise valuation snapshot drawn directly from the data set:
| Metric | Value |
|---|---|
| P/E (TTM) | -14.15 |
| P/B | 5.96 |
| EV/EBITDA | -7.99 |
| Gross Margin | 89.63 % |
| Operating Margin | -5,364.0 % |
| Net Margin | -2,825.7 % |
| ROE | -64.57 % |
| Debt/Equity | 6.29 |
| Analyst Target | $39.17 |
Historical Performance
A look back at the past four fiscal years highlights the volatility of Alumis’s earnings per share (EPS) and free cash flow (FCF).
- 2022 – EPS ‑$14.93, FCF outflow $110.1 M, P/E ‑0.89, ROE 57.33 % (an outlier driven by a very low earnings base).
- 2023 – EPS ‑$2.99, FCF outflow $134.5 M, P/E ‑4.45, ROE 45.69 %.
- 2024 – EPS ‑$10.38, FCF outflow $256.8 M, P/E ‑0.76, Gross Margin 85.46 %, operating and net margins sharply negative.
- 2025 – Revenue $24.05 M, EPS ‑$2.32, FCF outflow $370.2 M, P/E ‑34.11.
The consistent negative earnings and widening cash burn underscore the difficulty of sustaining a biotech that has yet to achieve product commercialization.
ETF Ownership
Alumis’s share float is modestly held by a handful of sector‑focused exchange‑traded funds. The top four ETF holders, as of the latest filing, are:
Collectively, these funds own roughly 3.68 % of the outstanding shares, a concentration that can amplify price swings when any of the funds rebalance. For instance, a modest reduction by XPH—a fund that ranks third in its category—could exert downward pressure on the stock, especially given the already thin trading volume typical of small‑cap biotech equities. Conversely, fresh allocations could provide a short‑term lift, but such inflows are unlikely to offset the fundamental headwinds outlined above.
LOPJLB Signal Read
The LOPJLB engine currently assigns ALMS a SELL directional signal with a composite Score of –5. The market regime is flagged as RECOVERY, indicating that the broader equity environment is transitioning from a contractionary phase toward modest upside, yet the signal remains bearish for Alumis specifically.
Performance (PERF) and fund quality (FUND) scores stand at 47.00 and 0.00, respectively, suggesting that while the stock’s price action has shown relative strength, the underlying quality metrics are weak. The quantitative breakdown places the stock at Value = 2.00, Growth = 20.00, GARP = 6.20, and Quality = 34.90, classifying it within a Balanced archetype.
Investors can explore the full overlay of technical and sentiment indicators on the interactive chart above the article. For a deeper dive into the methodology that generates these scores, visit the LOPJLB methodology page at https://www.lopjlb.com/methodology.
Closing Thoughts and Resources
Alumis Inc. remains a high‑risk, high‑potential play that is currently priced well below analyst expectations but is weighed down by severe earnings deficits, a steep cash‑burn trajectory, and a fragile balance sheet. The SELL signal reflects the convergence of weak fundamentals, volatile price action, and a market environment that, while in recovery, does not appear to favor distressed biotech equities at this juncture.
For the most up‑to‑date data, detailed charting tools, and a full breakdown of the signal components, visit the dedicated stock page: https://www.lopjlb.com/stock/ALMS.
Explore additional research, including any earnings‑call transcripts (if released) at https://www.lopjlb.com/stock/ALMS/earnings.md, and use the LOPJLB screener to compare Alumis against peers: https://www.lopjlb.com/screener.
The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consider their risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.